Breaking News, Trials & Filings

FDA Lifts Hold on MediLink’s BNT326/YL202 Phase I Trial

MediLink and BioNTech implement risk mitigation measures.

Author Image

By: Charlie Sternberg

Associate Editor

The U.S. Food and Drug Administration (FDA) has lifted the partial clinical hold placed on MediLink Therapeutics (Suzhou) Co., Ltd.’s Phase I trial evaluating BNT326/YL202 (NCT05653752).   The decision follows the submission of a comprehensive response by MediLink, addressing the FDA’s concerns regarding safety data and incorporating additional risk mitigation measures.   BNT326/YL202 is a HER3-targeting antibody-drug conjugate (ADC) being developed in collaboration with BioNTech SE. T...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters